To improve the patient-centeredness of care, patient-reported outcomes have been
increasingly used to quantify patients' symptoms, function, and quality of life. In heart failure …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors
improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in …

Background Previous studies have suggested that haemodynamic-guided management
using an implantable pulmonary artery pressure monitor reduces heart failure …

Abstract The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart
Failure Treatment was created to provide a practical, streamlined resource for clinicians …

Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …